Tylenol and Listerine maker reported $456 million in quarterly profit as higher prices and volumes supported its turnaround efforts.
Kenvue reported higher second-quarter profit and sales as price increases and stronger volumes lifted results while the consumer health company works to improve performance ahead of its acquisition by Kimberly-Clark. The company, which makes over-the-counter health products including Tylenol and Listerine, posted profit of $456 million, or 24 cents a share, for the three months ended June 28, up from $420 million, or 22 cents a share, in the comparable period a year earlier.